Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 14/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
| ▸ | ESR1 | P03372 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10194862 | 0.84 | MEN1 (0.38) | TMEM97SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19200356 | 0.83 | ESR2 (0.41) | ESR2TMEM97QDPRESR1SLC6A2 | |
| SCHEMBL2160044 | 0.82 | KDM1A (0.44) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2159199 | 0.82 | HTR3A (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13575754 | 0.82 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17948228 | 0.81 | SLC18A3 (0.48) | — | |
| SCHEMBL15317743 | 0.79 | HTR2C (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16915218 | 0.79 | DRD2 (0.42) | TMEM97 | |
| SCHEMBL16874839 | 0.79 | TLR9 (0.40) | ESR2QDPRESR1SLC6A2SLC6A4 | |
| SCHEMBL4890404 | 0.78 | HTR2C (0.56) | TMEM97SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |